Join us for the Policy Summit Sept. 25-26 at the Washington Marriott Georgetown in Washington, D.C.!
In Q2, three new therapeutics were approved and the number of gene therapy programs continued to climb.
The second quarterly report of 2025 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
FDA approved Zevaskyn for recessive dystrophic epidermolysis bullosa (RDEB) and mNexspike for COVID-19
In China, the country’s first gene therapy for hemophilia B was approved
Sixty-four percent of the 80 gene therapy trials initiated were for oncology indications, the highest proportion of the past year
Read + Download the Full Report
CGTs for Cancer, In Vivo Editing & More
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico